← Back to Search

Neuroimaging for Migraine

N/A
Waitlist Available
Led By Catherine Chong, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female only.
Ages 20-45 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial is investigating whether WMH are more common in women with migraines, and if so, what characteristics they have.

Who is the study for?
This study is specifically for women aged 20-45 who have white matter hyperintensities (WMH) on their brain MRI, which can be related to conditions like migraines or small vessel disease.Check my eligibility
What is being tested?
The trial is focused on using brain neuroimaging techniques to investigate the presence and characteristics of WMH in women suffering from migraines.See study design
What are the potential side effects?
Since this trial involves non-invasive brain imaging, there are minimal side effects. Participants may experience discomfort from lying still during the MRI procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am female.
Select...
I am between 20 and 45 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
WMH imaging disease parameters

Trial Design

3Treatment groups
Experimental Treatment
Group I: Small vessel ischemic (SVI) disease cohortExperimental Treatment1 Intervention
Women diagnosed with SVI disease and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
Group II: Multiple sclerosis (MS) cohortExperimental Treatment1 Intervention
Women diagnosed with MS and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
Group III: Migraine cohortExperimental Treatment1 Intervention
Women with migraine and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,239 Previous Clinical Trials
3,771,549 Total Patients Enrolled
10 Trials studying Migraine
81,956 Patients Enrolled for Migraine
Catherine Chong, PhDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
260 Total Patients Enrolled
~1 spots leftby Aug 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top